Triple Analysis: Colorectal Cancer, Pancreatic Cancer and Antibodies

BioSeeker Group AB
November 1, 2012
4520 Pages - SKU: BIOS4910024
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Pancreatic Cancer and by the compound strategy of Antibodies. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.



More Oncology/Hematology reports by BioSeeker Group AB

Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014 by BioSeeker Group AB
Wnt Signaling Pathway in Oncology Drug Pipeline Update 2014Abnormalities in the Wnt signaling pathway are associated with a large variety of human malignancies including tumors ...
Viral Carcinogenesis Drug Pipeline Update 2014 by BioSeeker Group AB
Viral Carcinogenesis Drug Pipeline Update 2014There is a strong association between viruses and the development of human malignancies. We now know that at least six ...
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014 by BioSeeker Group AB
VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014There is now much evidence that VEGFR-2 is the major mediator of VEGF-driven responses in endothelial cells ...
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2014 by BioSeeker Group AB
TSLP Signaling Pathway in Oncology Drug Pipeline Update 2014Thymic stromal lymphopoietin (TSLP) is an IL-7-like cytokine that play various roles in a broad spectrum of ...
See all reports like this >>

 

SELECT A LICENSE

    PDF E-mail From Publisher  USD 5,175  
    Global Site License Fulfilled by Publisher  USD 12,937  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!